Welcome to Wisdom Bioscience

 Dr. Kennedy is the Co-Founder and Chief Scientific Officer of PinkDx, a molecular diagnostic company focused on women’s healthcare. Prior to co-founding PinkDx, she was Chief Scientific Officer and Chief Medical Officer of Veracyte, joining in 2008 as a member of the founding team. While at Veracyte, Dr. Kennedy led the development and commercialization of eight genomic tests that changed the standard of patient care, using machine learning to develop tests that answer critical clinical questions. Prior to Veracyte, Dr. Kennedy was Senior Director of Genomics Collaborations at Affymetrix, Inc. and led the transition of a novel microarray-based genotyping method from early research through product development and successful commercialization. Previously, Dr. Kennedy was a scientific leader for the colon cancer and breast cancer gene discovery efforts at Chiron Corporation. Before that, she was a scientist at Millennium Pharmaceuticals, where she implemented genetic approaches to study diabetes. In addition to joining as a member of the Board of Directors at Encodia, Inc in 2023, she has been a member of the Board of Directors at Acuamark, Inc. since 2021. Previously she was a member of the Medical Advisory Board at Intervenn, Inc and a member of the Board of Directors of Astarte, Inc. She is an advisor for the UCSF Catalyst program, a translational accelerator focused on advancing discoveries with clinical impact and commercial potential. In 2020 Dr. Kennedy was named one of the Bay Area’s 100 Most Influential Women in Business by the San Francisco Business Times.

Dr. Kennedy holds a Ph.D. degree in Biochemistry and completed postdoctoral training at the University of California at San Francisco in the Biochemistry Department and Hormone Research Institute. Dr. Kennedy has published more than 70 articles in peer-reviewed scientific journals and is a co-inventor on more than 30 patents.

Arnold J. Levine, PhD, Professor Emeritus at the Institute for Advanced Study in Princeton, N.J., received his B.A. in Biology from Harpur College, SUNY, his Ph.D. from the University of Pennsylvania, and was a Postdoctoral Fellow at the California Institute of Technology. From 1968 to 1979, Dr. Levine was a member of the  Princeton University faculty. In 1979, he moved to the SUNY Stony Brook School of Medicine to Chair the Department of Microbiology, the same year he and others discovered the p53 tumor suppressor protein. He returned to Princeton in 1984. Between 1984 and 1996, he presided over a major expansion of Princeton’s life sciences programs as Chairman of the Department of Molecular Biology. From 1998 to 2002, Dr. Levine was President of The Rockefeller University.

Professor Levine established the Simons Center for Systems Biology at the Institute for Advanced Study, concentrating on research at the interface of molecular biology and the physical sciences. He helped shape U.S. science priorities as chairman of an influential 1996 review panel on federal AIDS research funding, and chaired the National Cancer Advisory Board, advising the National Academy of Sciences and its Institute of Medicine on cancer policy. He has been recognized with numerous honors and awards, including election to the National Academy of Sciences, and its Institute of Medicine. 

 John Sninsky, PhD, is a molecular biologist and biotechnology executive recognized for his pioneering contributions to nucleic acid–based diagnostics and his leadership in translating molecular innovation into routine clinical practice. He earned his doctorate in microbiology and immunology and has built a career at the intersection of science, medicine, and diagnostics commercialization.

Dr. Sninsky was a senior scientist at Cetus Corporation, where he played a key role in the early development and clinical application of PCR-based technologies for infectious disease detection, helping to establish molecular diagnostics as a foundation of modern laboratory medicine.

He brings deep and broad experience in senior management roles across small and enterprise laboratory-developed test and in vitro diagnostic organizations. His work has focused on translating advanced technologies into reimbursed clinical practice for infectious and genetic diseases, oncology, and solid organ transplantation. His technology experience spans the development and commercialization of PCR, next-generation sequencing (NGS) of the human genome, genome-wide association studies, and liquid biopsy platforms.

Across his career, Dr. Sninsky has authored influential scientific publications, is an inventor on numerous patents, and has played a central role in advancing diagnostics, genomics, and translational biomedical innovation.

Tin Tin Su, PhD is a Professor of Molecular, Cellular, and Developmental Biology at the University of Colorado Boulder. Her research focuses on how cells and tissues respond to high-energy radiation, with the goal of improving cancer radiation therapy. Using the genetic model organism Drosophila melanogaster, her lab identifies genes and small molecules that influence radiation recovery and cancer cell survival.

Dr. Su received her PhD from Carnegie Mellon University and completed postdoctoral training at the University of California, San Francisco. In addition to her academic research and teaching, she is a co-founder and Chief Scientific Officer of SuviCa, Inc., a biotechnology company developing novel cancer therapeutics. She has authored numerous peer-reviewed publications, holds multiple patents, and is a Senior Member of the National Academy of Inventors.

Martin Goldberg, PhD, is Senior Vice President of Product Development at Seer, where he has overseen the development of the company’s Proteograph™ commercial product suite since its inception. He established and co-manages Seer’s service laboratories in California and Bonn, Germany. Previously, Dr. Goldberg served as SVP of Research & Development at Talis Biomedical, leading development of a nucleic acid–based, sample-to-answer point-of-care diagnostic platform. He later transitioned to SVP of Operations, where he built the company’s contract manufacturing and supply chain for disposable cartridges and instrumentation. As Chief Operating Officer at Gen9, he established the company’s high-yield, high-fidelity synthetic gene manufacturing infrastructure. 

Earlier in his career, Dr. Goldberg held multiple leadership roles at Affymetrix across research, operations, and commercial functions.

Dr. Goldberg began his career at the IBM Thomas Watson Research Center, working in polymer chemistry and advanced materials manufacturing. He holds a PhD in Chemistry from University of California San Diego.